Vivani Medical Inc (VANI)
1.60
-0.02
(-1.23%)
USD |
NASDAQ |
Jun 14, 16:00
1.56
-0.04
(-2.50%)
Pre-Market: 08:06
Vivani Medical Enterprise Value: 58.32M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
June 14, 2024 | 58.32M |
June 13, 2024 | 59.42M |
June 12, 2024 | 59.97M |
June 11, 2024 | 59.97M |
June 10, 2024 | 60.52M |
June 07, 2024 | 59.14M |
June 06, 2024 | 58.87M |
June 05, 2024 | 61.07M |
June 04, 2024 | 60.52M |
June 03, 2024 | 62.17M |
May 31, 2024 | 59.97M |
May 30, 2024 | 60.52M |
May 29, 2024 | 60.52M |
May 28, 2024 | 61.62M |
May 24, 2024 | 62.17M |
May 23, 2024 | 59.97M |
May 22, 2024 | 67.11M |
May 21, 2024 | 68.49M |
May 20, 2024 | 71.51M |
May 17, 2024 | 80.03M |
May 16, 2024 | 78.66M |
May 15, 2024 | 75.36M |
May 14, 2024 | 70.96M |
May 13, 2024 | 72.06M |
May 10, 2024 | 69.86M |
Date | Value |
---|---|
May 09, 2024 | 64.92M |
May 08, 2024 | 63.82M |
May 07, 2024 | 65.46M |
May 06, 2024 | 68.76M |
May 03, 2024 | 68.21M |
May 02, 2024 | 64.92M |
May 01, 2024 | 61.62M |
April 30, 2024 | 59.42M |
April 29, 2024 | 59.97M |
April 26, 2024 | 59.97M |
April 25, 2024 | 63.54M |
April 24, 2024 | 65.46M |
April 23, 2024 | 69.31M |
April 22, 2024 | 62.17M |
April 19, 2024 | 63.82M |
April 18, 2024 | 69.59M |
April 17, 2024 | 71.51M |
April 16, 2024 | 75.91M |
April 15, 2024 | 81.41M |
April 12, 2024 | 84.16M |
April 11, 2024 | 83.06M |
April 10, 2024 | 83.61M |
April 09, 2024 | 83.06M |
April 08, 2024 | 90.21M |
April 05, 2024 | 80.31M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-8.574M
Minimum
Dec 30 2022
203.03M
Maximum
Aug 31 2022
38.81M
Average
29.51M
Median
Aug 11 2023
Enterprise Value Benchmarks
CEL-SCI Corp | 65.10M |
AIM ImmunoTech Inc | 15.35M |
IGC Pharma Inc | 25.36M |
NovaBay Pharmaceuticals Inc | 3.382M |
Protalix BioTherapeutics Inc | 55.51M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -6.039M |
Total Expenses (Quarterly) | 6.227M |
EPS Diluted (Quarterly) | -0.12 |
Earnings Yield | -30.62% |